Testicular Germ Cell Tumor Management and Treatment

Testicular germ cell tumours represent the most common malignancy in young men and are broadly classified into seminomas and non-seminomas. Primary management involves radical orchiectomy for histological diagnosis followed by accurate staging to guide risk-adapted therapy. Surveillance strategies address stage I disease with regular imaging and tumour marker assessments, while adjuvant chemotherapy or radiotherapy is reserved for higher-risk presentations. Metastatic disease is highly curable owing to remarkable sensitivity to cisplatin-based combination regimens, though 10–20% of patients exhibit refractory or relapsed disease requiring intensification or salvage approaches. Long-term survivorship considerations include fertility preservation, management of late toxicities such as cardiovascular and secondary malignancies, and integration of novel biomarkers to refine prognostication. Advances in molecular stratification, liquid biopsy, immunotherapeutic targets and precision medicine are converging to individualise treatment while minimising morbidity.

Research from Nature Portfolio

Recent single-cell multi-omics profiling of seminoma tissues has generated a spatial atlas of tumour cell programmes and the immune landscape, revealing shared transcriptional circuits between malignant germ cells and their embryonic precursors. Key regulators such as TFAP2C have been implicated in tumour invasiveness, while distinct immune subpopulations with exhaustion phenotypes localise proximal to malignant regions, suggesting avenues for microenvironment-directed therapies. Complementing this, whole-exome sequencing studies have characterised the low mutational burden of germ cell tumours, confirmed recurrent alterations including 12p amplification and KIT mutations, and identified novel drivers such as CDC27 and FSIP2. Importantly, mutations in DNA-repair genes like XRCC2 have been linked to cisplatin resistance, offering molecular entry points for overcoming therapeutic failure.

Testicular Germ Cell Tumor Management and Treatment publication trend

The graph below shows the total number of articles in testicular germ cell tumor management and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Orchiectomy: Surgical removal of one or both testicles, serving both diagnostic and therapeutic roles in germ cell tumours.

Seminoma: A histological subtype characterised by uniform cells, high radiosensitivity and generally favourable prognosis.

Non-seminoma: A heterogeneous group including embryonal carcinoma, yolk sac tumour, choriocarcinoma and teratoma, often more aggressive and less radiosensitive.

Cisplatin: A platinum-based chemotherapy agent that induces DNA crosslinks and is the cornerstone of systemic therapy for germ cell tumours.

MicroRNA-371a-3p (M371 test): A circulating embryonic stem cell microRNA serving as a highly sensitive and specific biomarker for diagnosis and monitoring.

Tumour microenvironment (TME): The complex milieu of immune cells, stromal elements and signalling molecules surrounding cancer cells, which influences progression and therapeutic response.

References

1. Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment. Nature Communications (2023).
2. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nature Communications (2015).
3. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology (2019).
4. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology (2021).
5. Toxicities Associated with Cisplatin‐Based Chemotherapy and Radiotherapy in Long‐Term Testicular Cancer Survivors. Advances in Urology (2018).